Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) representing its most commonly diagnosed sub-type. Despite the significant improvements in lung cancer biomarkers knowledge, accompanied by substantial technological advances in molecular tumor profiling, a considerable fraction (up to 30%) of advanced NSCLC patient presents with major testing challenges or tissue unavailability for molecular analysis. In this context, liquid biopsy is on the rise, currently gaining considerable interest within the molecular pathology and oncology community. Molecular profiling of liquid biopsy specimens using next generation molecular biology methodologies is a rapidly evolving field with promising applications not exclusively limited to advanced stages but also more recently expanding to early stages cancer patients. Here, we offer an overview of some of the most consolidated and emerging applications of next generation sequencing technologies for liquid biopsy testing in NSCLC.

Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021 / Pisapia, Pasquale; Costa, José Luis; Pepe, Francesco; Russo, Gianluca; Gragnano, Gianluca; Russo, Alessandro; Iaccarino, Antonino; de Miguel-Perez, Diego; Serrano, Maria Josè; Denninghoff, Valeria; Quagliata, Luca; Rolfo, Christian; Malapelle, Umberto. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - (2021), p. 103311. [10.1016/j.critrevonc.2021.103311]

Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021

Pisapia, Pasquale;Pepe, Francesco;Russo, Gianluca;Gragnano, Gianluca;Iaccarino, Antonino;Malapelle, Umberto
2021

Abstract

Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) representing its most commonly diagnosed sub-type. Despite the significant improvements in lung cancer biomarkers knowledge, accompanied by substantial technological advances in molecular tumor profiling, a considerable fraction (up to 30%) of advanced NSCLC patient presents with major testing challenges or tissue unavailability for molecular analysis. In this context, liquid biopsy is on the rise, currently gaining considerable interest within the molecular pathology and oncology community. Molecular profiling of liquid biopsy specimens using next generation molecular biology methodologies is a rapidly evolving field with promising applications not exclusively limited to advanced stages but also more recently expanding to early stages cancer patients. Here, we offer an overview of some of the most consolidated and emerging applications of next generation sequencing technologies for liquid biopsy testing in NSCLC.
2021
Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021 / Pisapia, Pasquale; Costa, José Luis; Pepe, Francesco; Russo, Gianluca; Gragnano, Gianluca; Russo, Alessandro; Iaccarino, Antonino; de Miguel-Perez, Diego; Serrano, Maria Josè; Denninghoff, Valeria; Quagliata, Luca; Rolfo, Christian; Malapelle, Umberto. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - (2021), p. 103311. [10.1016/j.critrevonc.2021.103311]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/848827
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact